A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 12523 participants.
Also called NCT05702034
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 12,523 participants
- Registry
-
NCT05702034 -
2022-501176-26-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05702034. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-15 (actual); primary completion 2026-10-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Acronym
- LIBREXIA-STROK
- Condition
- Ischemic Stroke; Ischemic Attack, Transient
- Intervention (Drug)
- Milvexian
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- Bristol Myers Squibb Company (BMS)
Record details
- Record id
cardio:ct-nct05702034- Content hash
b3c7b78f397e6d3aa6a12d30f1f5d72f691853e962e6ea8c4be920874b9efcbd